公开(公告)号：US20240207406A1

公开(公告)日：2024-06-27

申请号：US18556054

申请日：2022-04-18

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Cassian YEE ,  Ke PAN ,  Yulun CHIU

IPC: A61K39/00 ,  A61K45/06 ,  C07K7/06 ,  C07K14/725 ,  C07K14/74 ,  C07K16/32 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/569

CPC classification number: A61K39/4644 ,  A61K39/0011 ,  A61K39/4611 ,  A61K39/4632 ,  A61K45/06 ,  C07K7/06 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/32 ,  C12N5/0636 ,  C12N15/115 ,  G01N33/56966 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2318/00 ,  C07K2319/30 ,  C07K2319/32 ,  C12N2502/1121 ,  C12N2510/00

Abstract: The current disclosure fulfills a need in the art by providing methods and compositions for treating and vaccinating individuals against cancer. Accordingly, aspects of the disclosure relate to an isolated peptide comprising at least 70% sequence identity to a peptide of SEQ ID NO: 1 or 2. In some embodiments, the peptide comprises at least 6 contiguous amino acids of a peptide of SEQ ID NO:1 or 2. Further aspects relate to pharmaceutical compositions comprising the isolated peptide, nucleic acids encoding the peptide, and expression vectors and host cells comprising the nucleic acids of the disclosure. Also provided is an in vitro isolated dendritic cell comprising a peptide, nucleic acid, or expression vector of the disclosure.

公开(公告)号：US20240207402A1

公开(公告)日：2024-06-27

申请号：US18554631

申请日：2022-04-07

Applicant: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts

Inventor： Angela Braun ,  Annika Frank ,  Christian Buchholz

IPC: A61K39/00 ,  A61K31/506 ,  A61K48/00 ,  C12N5/0783 ,  C12N15/86

CPC classification number: A61K39/4611 ,  A61K31/506 ,  A61K48/0058 ,  C12N5/0636 ,  C12N15/86 ,  C12N2510/00 ,  C12N2740/15043

Abstract: The present invention concerns the field of gene transfer. More specifically, the present invention relates to method for enhancing receptor-targeted gene transfer into a primary T-cell as a host cell said method comprising contacting a host cell comprised in a sample with a gene transfer vehicle comprising a targeting agent which specifically binds to CD3 and a nucleic acid of interest to be transferred into the host cell in the presence of a tyrosine kinase inhibitor which is capable of inhibiting the LCK tyrosine kinase in said host cell and cultivating said host cell culture obtained for a time and under conditions which allow for receptor-targeted gene transfer. The present invention also relates to a method for the preparation of a medicament as well as a medicament comprising a gene transfer vehicle comprising a targeting agent which specifically binds to CD3 and a nucleic acid of interest to be transferred into primary T-cells and a tyrosine kinase inhibitor which is capable of inhibiting the LCK tyrosine kinase in said primary T-cells. Furthermore, also relates to a tyrosine kinase inhibitor for use in receptor-targeted gene transfer into said primary T-cell in a subject being in need thereof, wherein said tyrosine kinase inhibitor is capable of inhibiting the LCK tyrosine kinase in a primary T-cell as a host cell or gene transfer vehicle for use in enhancing receptor-targeted gene transfer into said primary T-cell in a subject being in need thereof, wherein the gene transfer vehicle is used in combination with a tyrosine kinase inhibitor which is capable of inhibiting the LCK tyrosine kinase in a primary T-cell as a host cell.

公开(公告)号：US20240207309A1

公开(公告)日：2024-06-27

申请号：US18420382

申请日：2024-01-23

Applicant: Myeloid Therapeutics, Inc.

Inventor： Samuel C. Wagner ,  Thomas E. Ichim ,  Julia S. Szymanski ,  Santosh Kesari ,  Amit N. Patel ,  Boris Minev

IPC: A61K35/15 ,  A61K38/17 ,  C07K16/00 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0786

CPC classification number: A61K35/15 ,  A61K38/177 ,  C07K16/00 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0645 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2501/599 ,  C12N2510/00

Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In 5 one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.

公开(公告)号：US12018255B2

公开(公告)日：2024-06-25

申请号：US16770877

申请日：2018-12-07

Applicant: University of Connecticut

Inventor： Stormy Chamberlain ,  Justin Cotney ,  Maéva Langouët ,  Marc Lalande

IPC: C07H21/04 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  A61K38/00

CPC classification number: C12N15/11 ,  C12N9/22 ,  C12N15/907 ,  A61K38/00 ,  C12N2310/20 ,  C12N2510/00 ,  C12N2800/80

Abstract: Disclosed herein are compositions, kits, and methods for treating a disorder of genomic imprinting in a subject. The method may include modifying a zinc-finger protein 274 (ZNF274) binding site on maternal chromosome 15 at position 15q11-q13 of the subject, such that the binding of a ZNF274 protein to the ZNF274 binding site is reduced relative to a control. The ZNF274 binding site comprises a polynucleotide having at least 90% sequence identify to SEQ ID NO: 1 or SEQ ID NO: 42. Further provided are DNA targeting systems that bind to a ZNF274 binding site or to a gene encoding a ZNF274 protein.

公开(公告)号：US20240200031A1

公开(公告)日：2024-06-20

申请号：US18555079

申请日：2022-04-12

Applicant: Memorial Sloan Kettering Cancer Center

Inventor： Katharine C Hsu ,  Mohammed Kazim Panjwani

IPC: C12N5/0783 ,  C07K14/74 ,  C12N15/86

CPC classification number: C12N5/0636 ,  C07K14/70539 ,  C12N5/0646 ,  C12N15/86 ,  C12N2501/2302 ,  C12N2502/99 ,  C12N2510/00 ,  C12N2740/15043

Abstract: In some aspects, the present invention involves chimeric recombinant HLA proteins that are derived from HLA-E proteins and comprise a leader peptide from an HLA-A, HLA-B, HLA-C or HLA-G protein. In some aspects, the present invention also involves nucleic acid molecules encoding such recombinant HLA proteins, vectors comprising such nucleic acid molecules, host cells comprising such recombinant HLA proteins, and various related compositions. In some aspects, the present invention also involves methods of use of such recombinant HLA proteins, nucleic acid molecules, vectors, host cells and compositions.

公开(公告)号：US20240197874A1

公开(公告)日：2024-06-20

申请号：US18287909

申请日：2022-06-01

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Joerg J. Goronzy ,  Cornelia M. Weyand ,  Jun Jin

IPC: A61K39/00 ,  A61K35/17 ,  A61P35/00 ,  C12N5/0783

CPC classification number: A61K39/4631 ,  A61K35/17 ,  A61K39/4611 ,  A61P35/00 ,  C12N5/0636 ,  A61K2239/57 ,  C12N2510/00

Abstract: Methods and materials for treating cancer (e.g., melanoma) in a subject and for improving efficacy of adoptive immune cell therapy are described. The methods can include administering immune cells (e.g., chimeric antigen receptor T cells or tumor-infiltrating lymphocytes) having reduced expression of a VPS39 polypeptide to the subject.

公开(公告)号：US12012615B2

公开(公告)日：2024-06-18

申请号：US16195054

申请日：2018-11-19

Applicant: Kyoto University

Inventor： Shinya Yamanaka ,  Kazutoshi Takahashi ,  Keisuke Okita

IPC: C12N5/00 ,  C12N5/074 ,  C12N15/85

CPC classification number: C12N5/0696 ,  C12N15/85 ,  C12N2501/60 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2506/11 ,  C12N2510/00

Abstract: The invention provides an in vitro method of improving the efficiency of establishment of induced pluripotent stem (iPS) cells. The method comprises contacting an isolated somatic cell being reprogrammed into an iPS cell with an inhibitor of p53 function. The invention also provides an in vitro method of producing iPS cells. The method comprises bringing (a) nuclear reprogramming substances or nucleic acids encoding the nuclear reprogramming substances and (b) an inhibitor of p53 function into contact with a somatic cell.

公开(公告)号：US12006513B2

公开(公告)日：2024-06-11

申请号：US17224924

申请日：2021-04-07

Applicant: University of Southern California

Inventor： Qi-Long Ying ,  Shi Yue

IPC: C12N5/0786 ,  C12N5/0787

CPC classification number: C12N5/0645 ,  C12N5/0642 ,  C12N2500/25 ,  C12N2500/30 ,  C12N2500/84 ,  C12N2501/10 ,  C12N2501/22 ,  C12N2501/415 ,  C12N2501/999 ,  C12N2510/00

Abstract: The disclosure provides methods for the long-term expansion of granulocyte-macrophage progenitors, the granulocyte-macrophage progenitors generated therefrom, and uses of the granulocyte-macrophage progenitors thereof.

公开(公告)号：US20240182597A1

公开(公告)日：2024-06-06

申请号：US18547663

申请日：2022-02-28

Applicant: TeneoBio, Inc.

Inventor： Katherine Harris ,  Brian Avanzino ,  Nathan Trinklein ,  Karen Chang ,  Nicole Allen

IPC: C07K16/30 ,  A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C12N5/0783

CPC classification number: C07K16/3092 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/46447 ,  A61P35/00 ,  C07K14/7051 ,  C12N5/0636 ,  C07K2317/569 ,  C07K2317/92 ,  C07K2319/33 ,  C12N2510/00

Abstract: Anti-MUC1-C antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of MUC1-C.

公开(公告)号：US20240181058A1

公开(公告)日：2024-06-06

申请号：US18281870

申请日：2021-04-05

Applicant: BIONOXX INC.

Inventor： Tae-Ho HWANG ,  Mong CHO

IPC: A61K39/00 ,  A61K35/768 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/08 ,  C12N5/0783

CPC classification number: A61K39/464838 ,  A61K35/768 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4631 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/081 ,  C12N5/0636 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00

Abstract: A chimeric antigen receptor targeting an oncolytic virus-derived protein, an immune cell expressing the same, and uses thereof are disclosed. The chimeric antigen receptor-expressing immune cell can effectively target the protein A56 that is specifically expressed on the cancer cell surface, which enables targeted therapy for cancer cells that have survived even infection with an oncolytic virus, thereby providing effective anticancer therapy. The chimeric antigen receptor-expressing immune cell can have increased activation and proliferation capacity specifically for protein A56 and exhibit excellent cytotoxic effects, thereby providing effective anticancer therapy against protein A56-expressing cancer cells. The immune cell is preferably used in combination with an oncolytic virus, and may be additionally used in combination with a drug capable of enhancing an anticancer effect of the oncolytic virus (for example, hydroxyurea, chemotherapeutic agents for regulating lymphocyte removal (for example, cyclophosphamide and fludarabine), or immunotherapeutic agents).